The software monitors patients with neovascular AMD
Artificial intelligence platform Retinsight has obtained MDR 2017/745 CE accreditation for the software to be used as a clinical decision support system for the monitoring of patients with neovascular age-related macular degeneration (nAMD).
The platform can be used with OCT scans from the Heidelberg Spectralis platform to help practitioners optimise therapy.
Developers said the software built on observer interpretations of biomarker, central retinal thickness and retinal fluid volumes by adding an AI-based ‘fluid activity meter’, which helped eye care specialists accurately identify and quantify the retinal fluid builds ups.